FDA splits up BPA report
This article was originally published in The Gray Sheet
Executive Summary
FDA released a draft assessment Aug. 15 downplaying the toxicity and health risks of the chemical bisphenol A (BPA) in food-contact applications, such as baby bottles and drink containers, and will issue a separate report focused on medical products at a later date, the agency says. NIH's National Toxicology Program released a report in April on the potential for BPA to leach from plastics in consumer products and some medical products (1"The Gray Sheet" May 12, 2008, p. 6). The BPA subcommittee of FDA's science board will meet Sept. 16 to discuss the food-related report
You may also be interested in...
FDA seeks data on BPA-containing devices
FDA is requesting information on devices and other medical products that contain the chemical Bisphenol A, whether as part of the product or its packaging, the agency announces Oct. 15. NIH's National Toxicology Program released a draft report in April, finalized Sept. 3, on the potential for BPA to leach from plastics in consumer products and some medical products. After convening an agency-wide taskforce, FDA released a draft assessment Aug. 15 downplaying the toxicity and health risks of BPA in food-contact applications only (1"The Gray Sheet" Aug. 18, 2008, In Brief). But Congressional leaders are investigating a potential conflict of interest because Dr. Martin Philbert, chair of FDA's BPA advisory panel, heads a research center that received a $5 million donation from retired medical equipment manufacturer Charles Gelman, who advocates BPA's safety. Comments on the presence and risks of BPA in devices and other medical products are due Dec. 29
FDA Task Force Takes Hard Look At Leachable Chemical In Medical Products
FDA is stepping up research into a chemical used in some plastics, including medical devices, in the wake of a recent National Institutes of Health brief outlining related safety concerns
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.